Neptune Medical's Triton Robot Achieves 100% Cecal Intubation Rate in First-in-Human Colonoscopy Study
核心洞察
Neptune Medical (搜索)'s Triton (搜索) gastrointestinal robot successfully met both primary endpoints in its CARE 1 first-in-human study, demonstrating 100% cecal intubation rate with no adverse events in 50 patients.
The robotic endoscopy system achieved a 67.5% polyp detection rate and 54.2% adenoma detection rate during screening, surveillance, and diagnostic colonoscopies performed at a single center in Poland.
Study investigators reported favorable ergonomic benefits for endoscopists, suggesting the system could enable performance of numerous high-quality colonoscopies with minimal fatigue to address increasing procedural demands.
Neptune Medical (搜索)'s Triton (搜索) gastrointestinal robot has demonstrated promising clinical performance in its first-in-human study, achieving 100% cecal intubation rate with no adverse events across 50 patients undergoing colonoscopy procedures. The CARE 1 study results, presented at Digestive Disease Week in Chicago, mark a significant milestone for the Burlingame, California-based company's robotic endoscopy platform.
Study Design and Primary Outcomes
The clinical trial evaluated the safety and feasibility of the Triton (搜索) robotic endoscopy system in 50 adults who underwent screening, surveillance, or diagnostic colonoscopy at a single center in Poland. Patients were monitored for 14 days following their procedures to assess safety outcomes.
The study successfully met both primary endpoints, with researchers reporting zero adverse events and achieving 100% cecal intubation rate. Cecal intubation represents successful navigation of the endoscope through the entire colon to reach the beginning of the large intestine, a critical technical milestone for complete colonoscopic examination.
Polyp and Adenoma Detection Performance
Beyond the primary safety and feasibility endpoints, the Triton (搜索) system demonstrated clinically relevant detection capabilities. The study recorded a 67.5% polyp detection rate and a 54.2% adenoma detection rate across the patient population. These metrics are crucial indicators of the system's diagnostic effectiveness, as adenoma detection directly correlates with colorectal cancer (搜索) prevention outcomes.
Ergonomic Advantages for Physicians
Study investigators highlighted the system's ergonomic benefits for endoscopists performing the procedures. Jason Samarasena, chief of gastroenterology and hepatology at the University of California, Irvine and study investigator, noted the potential for reduced physician fatigue during procedures.
"These early promising results suggest that Triton (搜索) may enable us to perform a large number of high-quality colonoscopies in a day with minimal fatigue, empowering us to respond to increasing colonoscopy demands in the United States," Samarasena stated.
Technology Platform and Clinical Applications
Neptune Medical (搜索) has designed the Triton (搜索) robot to enhance physician capabilities across multiple lower gastrointestinal procedures, including diagnostic colonoscopies, endoscopic mucosal resections, and endoscopic submucosal dissections. The system aims to address both technical performance and physician workflow challenges in gastroenterology practice.
Regulatory Status and Market Position
The Triton (搜索) system has not yet received authorization for commercial sale in the United States or international markets. The company continues to advance its clinical development program following the successful completion of this first-in-human study.
Neptune Medical (搜索) strengthened its financial position in 2024 with a $97 million Series D financing round, backed by investors including Sonder Capital (搜索) and Olympus. Following this funding round, the company spun out its Jupiter Endovascular (搜索) subsidiary to focus resources on gastrointestinal robotics development.